NCT06877169Recruiting
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
The primary purpose of this study is to evaluate the safety and efficacy of ex vivo machine perfusion with staged implantation of kidney allografts during combined heart/kidney transplantation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 4 Mar 2025
- Start date
- 7 Apr 2025
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- Cedars-Sinai Medical Center
- Diseases
- Chronic kidney disease, Heart failure
- NCT number
- NCT06877169
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 7 Apr 2025 to the primary completion date, 28 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who undergo simultaneous heart/kidney transplantation in a single operative event due to medical necessity will be excluded.
Other
- Patients with medical records flagged as "break-the-glass" or "research opt-out" within the center's electronic health record.
Who the study is looking for
- Adult patients (18 years or older) undergoing combined heart and kidney transplantation at Cedars-Sinai Medical Center.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cedars-Sinai Medical Center Coordinator of this site? Confirm its status | Los Angeles | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.